CompletedPhase 1

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

United States33 participantsStarted 2003-12

Plain-language summary

RATIONALE: Interferon alfa may interfere with the growth of tumor cells and slow the growth of urothelial cancer. PURPOSE: This randomized phase I trial is studying how well low-dose interferon alfa works in treating patients with cancer of the urothelium.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients must have histologically proven urothelial cancer, known or suspected (e.g. by outside evaluation) to be muscle-invasive, and be scheduled for cystoscopy and transurethral biopsy as part of their routine evaluation at M. D. Anderson.
✓. Patients must understand the investigational nature of this study and provide written, informed consent.

Exclusion criteria

✕. Patients who are pregnant or lactating are not eligible. Women of child-bearing potential must have a negative pregnancy test before starting therapy.
✕. Patients with current symptoms suggestive of clinically significant affective disorder.
✕. Patients taking more than physiologic replacement doses of corticosteroids are not eligible.

What they're measuring

Descriptive Data on Expression of Death Effectors in Context of Low-dose Interferon

Timeframe: 2 Years

Trial details

NCT IDNCT00082719

SponsorM.D. Anderson Cancer Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2015-01

View on ClinicalTrials.gov More Bladder Cancer trials